Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shenzhen - Delayed Quote CNY

Beijing Aosaikang Pharmaceutical Co., Ltd. (002755.SZ)

Compare
18.47
-0.52
(-2.74%)
At close: April 18 at 3:04:00 PM GMT+8
Loading Chart for 002755.SZ
  • Previous Close 18.99
  • Open 19.92
  • Bid 18.48 x --
  • Ask 18.50 x --
  • Day's Range 18.40 - 19.20
  • 52 Week Range 8.40 - 20.36
  • Volume 5,477,090
  • Avg. Volume 10,073,911
  • Market Cap (intraday) 17.143B
  • Beta (5Y Monthly) 0.39
  • PE Ratio (TTM) 102.61
  • EPS (TTM) 0.18
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jun 20, 2022
  • 1y Target Est 15.00

Beijing Aosaikang Pharmaceutical Co., Ltd. researches, develops, manufactures, markets, and sells pharmaceuticals, fine chemicals, and health-care products in China. It offers proton pump inhibitor injections and oncology medicines, as well as APIs. The company provides its products in digestive, oncology, antibiotic, and other areas. Beijing Aosaikang Pharmaceutical Co., Ltd. was founded in 2003 and is based in Nanjing, China.

www.ask-pharm.com

979

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 002755.SZ

View More

Performance Overview: 002755.SZ

Trailing total returns as of 4/18/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

002755.SZ
45.32%
SSE Composite Index (000001.SS)
2.24%

1-Year Return

002755.SZ
110.84%
SSE Composite Index (000001.SS)
6.59%

3-Year Return

002755.SZ
74.90%
SSE Composite Index (000001.SS)
2.54%

5-Year Return

002755.SZ
9.12%
SSE Composite Index (000001.SS)
15.44%

Compare To: 002755.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 002755.SZ

View More

Valuation Measures

Annual
As of 4/18/2025
  • Market Cap

    17.14B

  • Enterprise Value

    15.16B

  • Trailing P/E

    102.61

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.91

  • Price/Book (mrq)

    5.74

  • Enterprise Value/Revenue

    8.88

  • Enterprise Value/EBITDA

    107.54

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    9.55%

  • Return on Assets (ttm)

    0.59%

  • Return on Equity (ttm)

    4.09%

  • Revenue (ttm)

    1.71B

  • Net Income Avi to Common (ttm)

    163.14M

  • Diluted EPS (ttm)

    0.18

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.08B

  • Total Debt/Equity (mrq)

    3.28%

  • Levered Free Cash Flow (ttm)

    111.59M

Research Analysis: 002755.SZ

View More

Company Insights: 002755.SZ

Research Reports: 002755.SZ

View More

People Also Watch